The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 2)
Dyskinesia Challenge, 2015
Levodopa is the gold-standard drug for treatment of Parkinson's disease (PD), but chronic use is associated with serious motor complications called levodopa-induced dyskinesia (LID). Once established, LID is very hard to treat and adjustments in medication often result in reduced control of Parkinson's symptoms. The aim of this project is to find biofluid markers...
Researchers: Jan Bert Paul Gramsbergen, PhD
Community Fast Track, 2006
Study of the Role of Phosphorylation at Ser 129 in Alpha-synuclein Induced Dopaminergic Neurodegeneration in a Rodent Model of Parkinson's Disease
The involvement of alpha-synuclein in Parkinson's disease neurodegeneration is now widely accepted. However, factors and events contributing to the alpha-synuclein toxicity are still being investigated. Among modifications of alpha-synuclein, phosphorylation at Serine 129 has been related to the disease process based on data from postmortem studies and in vitro experiments. In fact, a recent study...